BioSpace News Archive

BioMidwest

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Clovis Oncology, Inc. announced that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due 2021.

September 20, 2021
·
7 min read
Biotech Bay

Imago BioSciences Announces Its Addition to the Russell 2000® Index

Imago BioSciences , Inc. today announced that it will be added to the Russell® 2000 Index as part of the planned second quarter IPO additions scheduled to join the Russell US Indexes on September 20, 2021.

September 20, 2021
·
3 min read
BioMidwest

Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum

Forge Biologics today announced that it has received additional designations and regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), advancing the manufacturing capabilities for its own and clients’ AAV gene therapies.

September 20, 2021
·
6 min read
BioMidwest

Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference

Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET.

September 20, 2021
·
1 min read
Genetown

Charles River Launches First Annual Healthcare Collaboration Report

Charles River Laboratories International, Inc. (NYSE: CRL) today released the results from its first annual Healthcare Collaboration Report

September 20, 2021
·
6 min read
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial

Triumvira Immunologics (“Triumvira”) today announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors.

September 20, 2021
·
3 min read
Drug Development

Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500.

September 20, 2021
·
8 min read
Breathing Circuits Market: Increase in Prevalence of Respiratory Diseases is expected to drive the Market

Breathing circuit is an assembly of components that connects the patient’s airway to the anesthesia machine through which controlled composition of gas mixture is dispensed.

September 20, 2021
·
6 min read
Colonoscopy Devices Market | Growing Number of Production of Colonoscopy Devices Drive the Market Growth

The presence of a technologically developed healthcare system and growing cases of rectal diseases are also propelling demand opportunities in the market.

September 20, 2021
·
4 min read
Compression Therapy Devices Market: Rising prevalence of vascular diseases to drive the market

Products in the global compression therapy devices market are utilized for the treatment of various chronic diseases including lymphedema, phlebitis, leg ulcers, and thrombosis along with other forms of varicose veins.

September 20, 2021
·
6 min read